Is LDL a real cause of heart disease, but not enough on its own?
Claim attributed to Nuanced cardiologists and lipidologists positioning between LDL "deniers" and LDL "absolutists"; the framing is also borrowed by some low-carb advocates to argue other markers matter more than LDL , A "middle ground" framing, not a single attributable quote. It is mainstream as multifactorial epidemiology, but the same phrasing is sometimes misused to imply LDL can be ignored if other markers look fine.
Both halves hold up as standard atherosclerosis biology: apoB retention is the necessary first step, while inflammation, Lp(a), and cumulative exposure decide when and whether disease becomes clinical. The only failure mode is rhetorical: stretching "not sufficient" into "not important," which the same evidence refutes.
LDL has to be there for plaque to start, but at everyday levels it is inflammation, Lp(a), and decades of exposure that decide if and when you actually have an event.
What it’s supposed to target
- ApoB retention (the necessary step)
- Endothelial injury and inflammation
- Lp(a) and other cofactors
- Cumulative exposure (concentration x time)
Start with the necessary step. Atherosclerosis begins when apoB-containing particles (LDL and its relatives) cross into the artery wall and are retained there; with essentially no retained apoB, there is essentially no plaque. That is why LDL is a genuine cause and not just a marker, and why the disease barely appears at the very low LDL levels seen in some populations and in people with protective genes. This necessity half of the claim is as solid as cardiology gets.
What that step does not do is fire on its own at everyday levels. Whether and when retained particles become a clinical event is paced by cofactors and time: blood pressure, smoking, inflammation (in the CANTOS trial an anti-inflammatory drug cut events without lowering LDL at all), Lp(a), and the sheer cumulative exposure of concentration multiplied by years. The boundary case proves the point: in homozygous familial hypercholesterolemia the LDL is so high that disease arrives in childhood with no other risk factor, so at extreme magnitude and time LDL alone is effectively sufficient. Hence 'causal, but not sufficient by itself' holds at ordinary levels, with that single caveat at the extremes.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
apoB particles must be retained in the artery wall for plaque to start: holds.
Cofactors (inflammation, hypertension, smoking, Lp(a)) and duration must modulate the rate of disease: holds.
At ordinary LDL levels, LDL alone does not decide whether a given person has a clinical event in a given window; that also takes plaque rupture and thrombosis, paced by inflammation, blood pressure and time: holds.
'Not sufficient' must not be read as 'unimportant': in homozygous familial hypercholesterolemia, LDL alone causes disease in childhood, so at the extreme it is decisive: holds.
What the evidence actually shows
Necessary, dose-dependent, and time-dependent
The 2017 European Atherosclerosis Society consensus concludes LDL is 'unequivocally' causal for atherosclerotic disease, synthesizing genetics, epidemiology, and trials across over 2 million participants and more than 150,000 cardiovascular events. The 2020 EAS statement adds the mechanism: apoB100 binds arterial-wall proteoglycans, driving selective retention of LDL in the intima, the necessary first step in a 'chronic and multifactorial lifelong disease process.' Critically, risk follows a log-linear association between cumulative LDL exposure and risk that increases with duration, so time is a real component, not just the number on a lipid panel.
Why LDL alone is not sufficient
Two independent lines show LDL control does not erase risk. In CANTOS (n=10,061 post-MI patients with elevated hsCRP), canakinumab at 150 mg cut major cardiovascular events (HR 0.85, 95% CI 0.74-0.98) without lowering LDL, proving inflammation is an independent driver. The 2022 EAS consensus finds high Lp(a) is causal, over 90% genetically set, and carries risk even at low LDL-C. The boundary case cuts the other way: in untreated homozygous familial hypercholesterolemia (LDL-C typically >500 mg/dL), atherosclerosis appears in the first decade of life absent the usual cofactors, so at extreme magnitude x time LDL alone is effectively sufficient.
Studies, graded, and who paid
EAS 2017 and 2020 consensus: LDL 'unequivocally' causal via apoB retention on arterial proteoglycans.
CANTOS cut events by lowering inflammation without touching LDL; Lp(a) adds risk even at low LDL-C.
EAS 2017 reports a log-linear dose-response that increases with duration of exposure.
Untreated homozygous FH (LDL-C >500 mg/dL) causes ASCVD in childhood without classic cofactors.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 1 | EAS 2017 consensus (Ference et al.) | Consensus / evidence synthesis | >2M participants, >150,000 CV events | Independent Non-commercial EAS society panel; individual author industry disclosures noted. | Synthesis judgment, not a single isolating trial; COI end-matter not rendered in fetched text. |
| 2 | EAS 2020 consensus (Boren, Chapman, Krauss et al.) | Consensus / mechanistic review | Narrative synthesis (no single n) | Independent Non-commercial EAS society statement; author disclosures noted. | Read at publisher/abstract level; fine numeric details not all extracted. |
| 3 | CANTOS (Ridker et al.) | Randomized controlled trial | 10,061 patients, median 3.7 y | Industry-funded Funded by Novartis, maker of canakinumab; result favours sponsor, but the LDL-independent mechanism is the relevant finding. | One anti-inflammatory drug; does not quantify total non-LDL attributable risk. |
| 4 | EAS 2022 Lp(a) consensus (Kronenberg et al.) | Consensus / evidence synthesis | Observational + genetic synthesis | Independent Non-commercial EAS society statement; author disclosures noted. | Read at publisher/abstract level. |
| 5 | Familial Hypercholesterolemia review (Bouhairie & Goldberg) | Narrative clinical review | Review (no primary cohort) | Independent Academic review, Washington University; no commercial sponsorship indicated. | Review, not original data; describes the extreme-magnitude boundary case. |
Residual risk despite controlled LDL (inflammation, Lp(a)) is itself the clinical proof that LDL alone is not sufficient; this companion check refines, not contradicts, the existing 'LDL is causal' check.
Unproven ≠ disproven
No controlled experiment can raise LDL while holding all cofactors and time constant, so 'sufficiency' is a component-cause synthesis judgment, not a single tested endpoint.
Where claim and evidence diverge
The cumulative concentration x time effect is reconstructed from genetics and multi-decade epidemiology; short trials structurally underestimate the lifelong dose-response.
The money trail
The strongest 'not sufficient' trial, CANTOS, was funded by Novartis, which sells the drug tested; the consensus statements are non-commercial society panels whose individual authors carry industry disclosures.
The honest read
Accurate as mainstream multifactorial epidemiology: apoB retention is necessary, cofactors and time set the pace, and LDL alone is not sufficient at ordinary levels but is effectively sufficient at very high lifelong exposure. The claim only misleads when 'not sufficient' is twisted into 'ignorable.'
What would change this verdict
Credible evidence that atherosclerosis develops at scale without apoB-particle retention would break the necessity half.
A demonstration that controlling LDL alone abolishes residual risk (no independent contribution from inflammation or Lp(a)) would overturn the 'not sufficient' half.
Sources
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. A consensus statement from the EAS Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. PMID 28444290.
- Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights. EAS Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. PMID 32052833.
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131. PMID 28845751.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: an EAS consensus statement. Eur Heart J. 2022;43(39):3925-3946. PMID 36036785.
- Bouhairie VE, Goldberg AC. Familial Hypercholesterolemia. Cardiol Clin. 2015;33(2):169-179. PMID 25939291.
People also ask
- Is LDL cholesterol really a cause of heart disease?
- Yes. The European Atherosclerosis Society consensus concludes that consistent genetic and clinical evidence unequivocally establishes that LDL causes atherosclerotic cardiovascular disease. The mechanism is apoB-particle retention in the artery wall, the necessary first step of plaque formation (Ference 2017; Boren 2020).
- If LDL is causal, why doesn't everyone with high LDL get heart disease?
- Because LDL is necessary but not sufficient on its own at ordinary levels. Whether and when plaque becomes a clinical event is paced by other factors and time: blood pressure, smoking, inflammation, Lp(a), and cumulative LDL exposure. In the CANTOS trial, an anti-inflammatory drug cut cardiovascular events without lowering LDL at all.
- Can high LDL cause heart disease on its own?
- At extreme, lifelong levels, effectively yes. In untreated homozygous familial hypercholesterolemia (LDL-C above 500 mg/dL), atherosclerosis appears in the first decade of life with no other classic risk factor. At everyday LDL levels, cofactors and duration of exposure co-determine if and when disease develops.
- Does 'LDL is not sufficient' mean I can ignore my LDL?
- No. 'Not sufficient' does not mean 'not important.' LDL is the necessary first step, and lowering it reduces events in proportion to the absolute reduction, by any mechanism. The claim only misleads when 'not sufficient alone' is stretched into 'LDL can be ignored if other markers look fine.'
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.